PMID- 2405106
OWN - NLM
STAT- MEDLINE
DCOM- 19900305
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 8
IP  - 2
DP  - 1990 Feb
TI  - Autologous bone marrow transplantation in acute myeloid leukemia in first 
      remission: results of a Dutch prospective study.
PG  - 287-94
AB  - Recent investigations have suggested a role for marrow ablative chemotherapy and 
      radiotherapy given with autologous bone marrow transplantation (auto-BMT) in the 
      treatment of acute myeloid leukemia (AML), but prospective studies have not been 
      reported. We assessed the comparative values of auto-BMT and allogeneic marrow 
      transplantation (allo-BMT) in 117 15- to 60-year-old consecutive patients 
      (median, 43 years) with AML following remission-induction therapy. In 32 cases of 
      the 90 (77%) complete responders, auto-BMT (nonpurged) was undertaken at a median 
      of 3.8 months and in 23 eligible cases human leukocyte antigen (HLA)-matched 
      allo-BMT occurred at 3.0 months after attainment of remission. Thus, nearly 60% 
      of complete responders had access to transplantation, the others being withdrawn 
      because of relapse, refusal, or other causes. Median time of regeneration to 
      neutrophils 0.5 x 10(9)/L and platelets 20 x 10(9)/L were 39 and 63 days 
      following auto-BMT versus 21 and 19 days after allo-BMT, respectively. AML 
      relapse was the predominant cause of failure after auto-BMT (17 of 32) and 
      procedure-related death was seen in three of 32 patients. The actuarial rates of 
      relapse at 3 years are 60% (auto-BMT) and 34% (allo-BMT) (log-rank, P = .03). 
      Patients treated with auto-BMT and allo-BMT have an overall survival of 37% and 
      66% at 3 years posttransplant, respectively (P = .05). Relapse-free 3-year 
      survival rates are 35% and 51%, respectively (P = .12). Survival of the 
      nongrafted complete responders is less than 10%. This study shows that allo-BMT 
      in adult patients with AML in first complete remission (CR) results in more rapid 
      hematopoietic reconstitution, is followed by fewer recurrences, and provides 
      better survival than auto-BMT.
FAU - Lowenberg, B
AU  - Lowenberg B
AD  - Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
FAU - Verdonck, L J
AU  - Verdonck LJ
FAU - Dekker, A W
AU  - Dekker AW
FAU - Willemze, R
AU  - Willemze R
FAU - Zwaan, F E
AU  - Zwaan FE
FAU - de Planque, M
AU  - de Planque M
FAU - Abels, J
AU  - Abels J
FAU - Sonneveld, P
AU  - Sonneveld P
FAU - van der Lelie, J
AU  - van der Lelie J
FAU - Goudsmit, R
AU  - Goudsmit R
AU  - et al.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
MH  - Actuarial Analysis
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bone Marrow/pathology
MH  - *Bone Marrow Transplantation/methods
MH  - Follow-Up Studies
MH  - Humans
MH  - Leukemia, Myeloid, Acute/drug therapy/mortality/radiotherapy/*surgery
MH  - Middle Aged
MH  - Netherlands
MH  - Prospective Studies
MH  - Remission Induction
MH  - Survival Rate
MH  - Whole-Body Irradiation
EDAT- 1990/02/01 00:00
MHDA- 1990/02/01 00:01
CRDT- 1990/02/01 00:00
PHST- 1990/02/01 00:00 [pubmed]
PHST- 1990/02/01 00:01 [medline]
PHST- 1990/02/01 00:00 [entrez]
AID - 10.1200/JCO.1990.8.2.287 [doi]
PST - ppublish
SO  - J Clin Oncol. 1990 Feb;8(2):287-94. doi: 10.1200/JCO.1990.8.2.287.